debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC

August 2000

There's lots of debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC.

The FDA is holding meetings...and considering a switch.

The Amer Pharmaceutical Assoc strongly supports it.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC
Sarafem, a new version of fluoxetine
new guidelines for treating PMS
Diabetes new One Touch FastTake test strips now allow patients to use a blood sample from their ARM
Diabetes more aggressive treatment of hypertension in patients with diabetes
Gastroenterology concern about serious GI side effects with Lotronex
Osteoporosis statins to reduce the risk of osteoporosis
Osteoporosis don't realize they still need calcium and vitamin D
Osteoporosis Fosamax (alendronate) just ONCE A WEEK
Insomnia natural meds for sleep
Infectious Diseases antibiotics to treat certain strains of E. coli INCREASES the risk of complications
Infectious Diseases Malarone, a new drug to prevent malaria
new ways to relieve hot flashes
Pregnancy which psychotropics they can give to women during pregnancy
Vaccines New CDC recommendations for flu shots